Cytokinetics, Incorporated

Cytokinetics, Incorporated is a late-stage biopharmaceutical company specializing in the discovery, development, and commercialization of muscle activators and inhibitors for potential treatments of debilitating diseases. The company's primary focus is on developing small molecule drug candidates designed to impact muscle function and contractility. Its product pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III clinical trial for heart failure, and reldesemtiv, a skeletal muscle troponin activator in Phase III clinical trial for amyotrophic lateral sclerosis and spinal muscular atrophy.

Products

• Omecamtiv mecarbil

• Reldesemtiv

• CK-136

• Aficamten

• CK-3772271